Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mikul, Sharma"'
Autor:
James D. Douketis, Andrea de Jong, Thalia S. Field, Anita Mountain, Jafna L. Cox, Anne Simard, David J. Gladstone, Alexandre Y Poppe, Mikul Sharma, William Semchuk, Jacob A. Udell, Shelagh B. Coutts, M. Patrice Lindsay, Gord Gubitz, Leanne K. Casaubon, Theodore Wein, Alan Bell, Shamir R. Mehta, Laura C. Gioia, Jeffrey Habert, Norine Foley, Christine Papoushek, Stephanie Lawrence, Eric E. Smith, Dar Dowlatshahi, Eddy Lang
Publikováno v:
CMAJ
POINTS CLES En 2016, au Canada (a l’exclusion du Quebec), 270 204 personnes ont ete admises a l’hopital pour un trouble cardiaque, un accident vasculaire cerebral (AVC) ou un deficit cognitif d’origine vasculaire; de ce nombre, 107 391 etaient
Autor:
Jafna L. Cox, Andrea de Jong, Anne Simard, Eddy Lang, Mikul Sharma, Theodore Wein, James D. Douketis, Gord Gubitz, Christine Papoushek, Jacob A. Udell, Eric E. Smith, Alan Bell, Norine Foley, Jeffrey Habert, Stephanie Lawrence, William Semchuk, Anita Mountain, Leanne K. Casaubon, Shelagh B. Coutts, David J. Gladstone, Shamir R. Mehta, Dar Dowlatshahi, Alexandre Y Poppe, Thalia S. Field, M. Patrice Lindsay, Laura C. Gioia
Publikováno v:
CMAJ
KEY POINTS In 2016, 270 204 people in Canada (excluding Quebec) were admitted to hospital for heart conditions, stroke and vascular cognitive impairment, including 107 391 women and 162 813 men, of whom 91 524 died.[1][1] This equates to 1 out of eve
Autor:
Jackie, Bosch, Martin, O'Donnell, Balakumar, Swaminathan, Eva Marie, Lonn, Mikul, Sharma, Gilles, Dagenais, Rafael, Diaz, Kamlesh, Khunti, Basil S, Lewis, Alvaro, Avezum, Claes, Held, Matyas, Keltai, Christopher, Reid, William D, Toff, Antonio, Dans, Lawrence A, Leiter, Karen, Sliwa, Shun Fu, Lee, Janice M, Pogue, Robert, Hart, Salim, Yusuf, W D, Toff
Publikováno v:
Neurology. 92:e1435-e1446
ObjectiveTo assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk.MethodsThe Heart Outcomes Prevention Evaluation-3 (